by Chanita Phetdee, Suwatjanee Naephrai, Malinee Pradain, Yanisa Panporm, Ubaid Ahmad, Panchika Prangkio Breast cancer is the most frequently diagnosed cancer and remains the leading cause of death among females. Despite the rapid advancement in cancer therapy, the development of more effective therapeutic strategies and anticancer agents with a new mode of action remains a critical challenge.
Combination of therapeutic agents is an attractive approach to enhance drug efficacy. Nisin, a cationic antimicrobial peptide, has been reported for its cytotoxicity against some cancer cell lines via several mechanisms, particularly membrane disruption.
Nisin can bind preferentially to the negatively charged phospholipids, causing pore formation in cell membranes. In this study, we demonstrated that nisin exhibited membrane permeabilization preferentially with anionic lipids using liposomal leakage assay.
Moreover, anticancer activity of nisin and doxorubicin (DOX) was investigated against two breast cancer cell lines, MCF-7 and MDA-MB-231, using MTT assay. Nisin demonstrated cytotoxic effect against breast cancer MCF-7 and MDA-MB-231, with IC 50 values of 5–8 µM, while exhibiting lower cytotoxicity toward normal cells.
PLOS ONE (Medicine) published a clinical update in Research Highlights on 23 Jun 2026.
The item focuses on Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability.
Review the original article for the full source wording and details.